Inovio Pharmaceuticals(US:INO) Prnewswire·2026-03-29 12:52Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Inovio Pharmaceuticals due to allegations of violations of federal securities laws, with a deadline for investors to seek lead plaintiff status by April 7, 2026 [2][4]. Group 1: Allegations Against Inovio Pharmaceuticals - The complaint alleges that Inovio and its executives made false and misleading statements regarding the manufacturing of the CELLECTRA device, which was deficient [4][10]. - It is claimed that Inovio is unlikely to submit the Biologics License Application (BLA) for INO-3107 to the FDA by the second half of 2024 due to insufficient information [4][10]. - The overall regulatory and commercial prospects of INO-3107 were overstated, leading to materially false and misleading public statements by the defendants [4][10]. Group 2: FDA Interaction and Stock Impact - On December 29, 2025, the FDA accepted Inovio's BLA for INO-3107 for standard review but noted inadequate information for accelerated approval [5][10]. - Following this announcement, Inovio's stock price fell by $0.56 per share, representing a 24.45% decrease, closing at $1.73 per share [6][10]. Group 3: Legal Proceedings and Investor Actions - The lead plaintiff in the class action will be the investor with the largest financial interest who is typical of class members [7][10]. - Faruqi & Faruqi encourages anyone with information regarding Inovio's conduct to contact the firm, including whistleblowers and former employees [8][10].